NUVB: IBTROZI and safusidenib drive strong growth, with major clinical and commercial milestones ahead
IBTROZI leads the ROS1 TKI market with strong efficacy and safety, while safusidenib shows unprecedented results in glioma and is poised for earlier regulatory milestones. The addressable markets for both drugs are substantial, with global expansion and platform innovation supporting future growth…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.